威尼斯569vip游戏 - 官方登录入口

Dragon Sail

One-stop, customized CDMO/CMO solutions

Dragon Sail Pharmaceutical Co., Ltd. is a high-tech enterprise focusing on antibody drug CDMO services, and it is dedicated to providing one-stop services for partners from sequence to IND, clinical sample production to BLA and commercial production of antibody drugs.

Dragon Sail Pharmaceutical Co., Ltd. is a high-tech enterprise focusing on antibody drug CDMO services, and it is dedicated to providing one-stop services for partners from sequence to IND, clinical sample production to BLA and commercial production of antibody drugs. Dragon Sail Pharmaceutical has built the first cross-free antibody plant in China in Lin-gang Special Area of China (Shanghai) Pilot Free Trade Zone, with a total investment of nearly RMB 700 million and a production scale of up to 12,000L. The site complies with Chinese, American and European GMP standards, and its unique NONCROS® cross-free antibody production platform complies with requirements for co-linear production of multiple products, featuring high overall operational efficiency and cost-effectiveness. Leveraging its integrated biopharmaceutical technology platform, Dragon Sail will accelerate the process of discovery, development and production of biological drugs especially for antibody drugs, empowering partners and benefiting patients.

Honorary Certificate

Member

Honorary MEDALS

High-tech Enterprise

The Annual Star

EU QP audit

Development History

2022

In May 2022, Dragon Sail was selected as an intelligent factory in Lingang.

In June 2022, Dragon Sail was selected as the special project for the cultivation of science and technology giants in Lingang.

In September 2022, Dragon Sail was identified as the first list of "specialized, special and new" enterprises in Lingang.

In December 2022, the first project of EU formulation production was delivered to the client.

2021

In October 2021, the first batch of 2000L Drug Substance and Production in a GMP standard were successfully delivered to client.

In October 2021, the manufacturing pilot of Lingang successfully passed the EU QP auditing.

In October 2021, Drag Sail won the prize of Lingang’s hope stars.

In December, Dragon Sail won the first list of R&D and Innovation institutions of enterprises in Lingan.

2020

In September 2020, the first cross-free antibody plant was officially operated.

In November 2020, Dragon Sail was awarded by an identification of high-tech enterprise.

In November 2020, Dragon Sail won the prize of "Future Star of 2020’s Chinese Biomedical CDMO Enterprises"

2019

The pilot manufacturing facility of Lingang Blue Bay started to operate in January 2019.

In September 2019, the first FDA&NMPA- based IND project was successfully delivered to client.

2016

Dragon Sail Pharmaceutical Co., Ltd. was established in October 2016.

2022

2021

2020

2019

2016

电话咨询